Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow (BM) lymphocyte status at the diagnosis and during different TKI therapies and correlate it with treatment responses.

Detaljer

Författare
  • Mohamed El Missiry
  • Shady Adnan Awad
  • Hanna L Rajala
  • Ahmed Al-Samadi
  • Marja Ekblom
  • Berit Markevän
  • Ingbritt Åstrand-Grundström
  • Maren Wold
  • Ellen Rabben Svedahl
  • Birgitte Ravn Juhl
  • Ole Weis Bjerrum
  • Inger Haulin
  • Kimmo Porkka
  • Ulla Olsson-Strömberg
  • Henrik Hjorth-Hansen
  • Satu Mustjoki
Externa organisationer
  • Skåne University Hospital
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Hematologi
Originalspråkengelska
Sidor (från-till)1041-1050
TidskriftJournal of Cancer Research and Clinical Oncology
Volym142
Utgivningsnummer5
Tidigt onlinedatum2016 jan 8
StatusPublished - 2016
PublikationskategoriForskning
Peer review utfördJa
Externt publiceradJa